Jantovia-Mxr 50/1000mg Tablet

Jantovia-Mxr 50/1000mg Tablet is a pharmaceutical formulation combining two active ingredients: sitagliptin & metformin. Sitagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, while metformin is classified as a biguanide antidiabetic agent. This tablet is designed to provide effective management of type 2 diabetes mellitus by targeting different mechanisms involved in glucose regulation.

Uses:

Jantovia-Mxr 50/1000mg Tablet is prescribed for the following purposes:

1. Control of blood glucose levels in patients diagnosed with type 2 diabetes mellitus.
2. Improvement of glycemic control in combination with dietary modifications and exercise.
3. Reduction of hemoglobin A1c (HbA1c) levels, indicating long-term glucose management.
4. Prevention of complications associated with uncontrolled diabetes, such as cardiovascular disease and neuropathy.

Side Effects:

While Jantovia-Mxr 50/1000mg Tablet is generally well-tolerated, some individuals may experience the following side effects:

1. Nausea and vomiting
2. Diarrhea
3. Abdominal discomfort or pain
4. Headache
5. Hypoglycemia (low blood sugar) when used concomitantly with other antidiabetic medications
6. Upper respiratory tract infections

It is important to consult a healthcare professional if any adverse reactions occur.

Precautions:

Before using Jantovia-Mxr 50/1000mg Tablet, consider the following precautions:

1. Inform your healthcare provider about any pre-existing medical conditions, especially kidney or liver disorders.
2. Use caution in elderly patients as they may be more susceptible to lactic acidosis, a rare but serious side effect associated with metformin.
3. Regular monitoring of kidney function and blood glucose levels is advisable during treatment.
4. Limit alcohol consumption while taking this medication as it may increase the risk of lactic acidosis.
5. Disclose all other medications, including over-the-counter drugs and supplements, to your healthcare provider to avoid potential drug interactions.

When Not to Use:

Avoid using Jantovia-Mxr 50/1000mg Tablet in the following circumstances:

1. Known hypersensitivity or allergy to sitagliptin, metformin, or any of the tablet’s components.
2. Severe kidney impairment (creatinine clearance <30 mL/min) or end-stage renal disease.
3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
4. History of lactic acidosis or predisposing factors such as heart failure or respiratory insufficiency.
5. Pregnancy or breastfeeding, unless the potential benefits outweigh the risks and under medical supervision.

In conclusion, Jantovia-Mxr 50/1000mg Tablet is an effective combination medication for managing type 2 diabetes mellitus. When used as directed under medical supervision, it helps control blood sugar levels and reduces the risk of diabetes-related complications.